Professor Jianming Guo Shares Zhongshan’s Approach to Postoperative Management of Prostate Cancer Complications2025 Pujiang Prostate Cancer Academic Conference

Professor Jianming Guo Shares Zhongshan’s Approach to Postoperative Management of Prostate Cancer Complications2025 Pujiang Prostate Cancer Academic Conference

2025.07.14
The 2025 Pujiang Prostate Cancer Academic Conference—jointly held with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GO), and the Chinese Prostate Cancer Consortium (CPCC)—took place in Shanghai on June 27–28. At the conference, Professor Jianming Guo from Zhongshan Hospital, Fudan University, delivered a keynote presentation on “Managing Postoperative Complications After Prostate Cancer Surgery” and later shared additional insights in an interview with Oncology Frontier – UroStream, highlighting Zhongshan’s experience in perioperative enhanced recovery after surgery (ERAS) for prostate cancer patients.
ASCO China Focus | “Rebirth: I Want to Keep My Bladder”—Professor Yijun Shen Presents Phase II ReBirth Study on Stratified Bladder-Sparing Approaches After Neoadjuvant Immunochemotherapy

ASCO China Focus | “Rebirth: I Want to Keep My Bladder”—Professor Yijun Shen Presents Phase II ReBirth Study on Stratified Bladder-Sparing Approaches After Neoadjuvant Immunochemotherapy

2025.07.10
To live or to live well?” This Shakespearean dilemma continues to haunt many patients with bladder cancer. How to provide longer-lasting disease control while preserving the bladder through safer and more tolerable strategies has become a central challenge in urologic oncology. At the 2025 ASCO Annual Meeting, Professor Yijun Shen from Fudan University Shanghai Cancer Center presented the Phase II ReBirth study, which evaluates stratified bladder-sparing treatment strategies based on whether patients achieve clinical complete response (cCR) following neoadjuvant immunochemotherapy.
Voices from China at ASCO | Professor Ting Li: Innovative Triple Combination with Adebrelimab, Bevacizumab,cisplatin/carboplatin Brings New Hope to TNBC Patients with Brain Metastases

Voices from China at ASCO | Professor Ting Li: Innovative Triple Combination with Adebrelimab, Bevacizumab,cisplatin/carboplatin Brings New Hope to TNBC Patients with Brain Metastases

2025.07.09
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 30 to June 3. At the conference, Professor Ting Li of Fudan University Shanghai Cancer Center delivered a Rapid Oral Abstract presentation on behalf of her team, showcasing a phase II clinical study (Abstract #1018) titled "A phase II clinical study of adebrelimab and bevacizumab combined with cisplatin/carboplatin in triple-negative breast cancer patients with brain metastases." Following her presentation, Oncology Frontier conducted an exclusive interview with Professor Li, where she shared insights into the rationale behind the study design, the benefits of the triplet therapy, and the specific patient groups most likely to benefit.
Voices from China at ASCO | Professor Jieqiong Liu：Exploring a new path for the treatment of metastatic breast cancer——analysis of the microenvironment of combination therapy

Voices from China at ASCO | Professor Jieqiong Liu：Exploring a new path for the treatment of metastatic breast cancer——analysis of the microenvironment of combination therapy

2025.07.09
A dynamic understanding of the tumor microenvironment (TME) is essential for uncovering the mechanisms behind treatment response and disease progression. At the 2025 ASCO Annual Meeting, Professor Jieqiong Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, presented an innovative translational study (Abstract #1022) exploring the efficacy and safety of a novel combination therapy in patients with HER2-positive metastatic breast cancer who had failed second-line or later treatments. The team employed single-cell sequencing to analyze TME changes before and after treatment with KN046, a bispecific anti-CTLA-4/PD-L1 antibody, and KN026, a bispecific anti-HER2 antibody. The results revealed distinct immunological  differences between responders and non-responders and identified the baseline macrophage-to-lymphatic endothelial cell (Mϕ/LEC) ratio as a predictive biomarker of treatment response. This study offers new insights into individualized care strategies for breast cancer.